Factor Model (net -1.4)
Factor Model
net -1.4 3.8 / 10FDA approves Bysanti tablets, stock surges 34%
Watch: Watch Q2 and Q3 prescriptions and revenue guidance for Bysanti. That will tell you whether this approval translates to a durable business driver or becomes a one-time pop that fades as market expectations reset.
Vanda Pharmaceuticals got FDA approval for Bysanti tablets on Monday, sending shares up 34.37% in premarket trading. The approval marks a regulatory win and near-term validation of the company's pipeline. Vanda's stock is showing strength across near-term, medium-term, and longer-term momentum indicators.
This is a binary catalyst event — hard regulatory approval that de-risks a key product and opens a new revenue stream. The market's immediate 34% pop reflects the approval's significance, but the real test is execution: whether Bysanti gains market adoption and drives sustained revenue growth for a biotech that's historically been execution-dependent.
Evidence
5 older signals
Fundamentals & Data ▾
Recent transactions
Get alerted when VNDA changes direction
We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.